1 / 50

Considerar otros diagnósticos

Sospecha de IC en base a signos y síntomas. Considerar otros diagnósticos. normal. anormal. Ecocardiografía-Doppler. ..continuar. Guías para el diagnóstico de IC aguda de la ESC. Determinar la presencia de cardiopatía mediante ECG, RX-tórax, Péptidos natriuréticos.

jaunie
Télécharger la présentation

Considerar otros diagnósticos

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sospecha de IC en base a signos y síntomas Considerar otros diagnósticos normal anormal Ecocardiografía-Doppler ..continuar Guías para el diagnóstico de IC aguda de la ESC Determinar la presencia de cardiopatía mediante ECG, RX-tórax, Péptidos natriuréticos Nieminen MS et al. Eur Heart J 2005; 26:384

  2. ANP BNP Aurícula Localización cardíaca Aurícula y ventrículo Elevada Concentración auricular Baja Secreción cardíaca basal ++ (+) Respuesta de la transcripción genética al estímulo Lenta Rápida Estabilidad mRNA Estable Inestable + +++ Aumento en relación con la insuficiencia cardíaca ANP y BNP: comparación fisiológica

  3. Péptidos natriuréticos: Sintesis -26 amino acid 108 pre-proBNP cardiomiocito 1 108 -26 -1 proBNP signal 1 76 77 108 NT-proBNP sangre BNP

  4. BNP- Diagnosis of acute dyspnea BNP Study: Breathing Not Properly Maisel et al, NEJM 2002;347:161

  5. Estudio ICON • Número total=1256 pacientes • No ICC=536 pacientes • Antecedentes de ICC=55 • No antecedentes de ICC=481 • IC aguda=720 pacientes

  6. ICON Diagnostico y NT-proBNP

  7. ICON 1 0.9 0.8 0.7 Area under the curve=0.94 P<0.00001 Optimal cut: 1160 pg/ml 0.6 Sensitivity (true positives) 0.5 0.4 0.3 0.2 0.1 0 0 0.2 0.4 0.6 0.8 1 1 - Specificity (false positives) Effect of Age on Cut-point Performance • Age <50 years • 84% sensitive/97% specific • Age 50-75 years • 85% sensitive/85% specific • Age >75 years • 94% sensitive/59% specific

  8. 1 0.9 0.8 0.7 0.6 Area under the curve=0.99 P<0.00001 Optimal cut: 450 pg/ml 97% sensitive, 93% specific Sensitivity (true positives) 0.5 0.4 0.3 0.2 0.1 0 0 0.2 0.4 0.6 0.8 1 1 - Specificity (false positives) ROC Analysis: Age<50 years

  9. 1 0.9 0.8 Area under the curve=0.93 P<0.00001 Optimal cut: 900 pg/ml 89% sensitive, 82% specific 0.7 0.6 0.5 Sensitivity (true positives) 0.4 0.3 0.2 0.1 0 0 0.2 0.4 0.6 0.8 1 1 - Specificity (false positives) ROC Analysis: Age 50-75 years

  10. 1 0.9 0.8 0.7 Area under the curve=0.86 P<0.00001 Optimal cut: 1800 pg/ml 85% sensitive, 73% specific 0.6 Sensitivity (true positives) 0.5 0.4 0.3 0.2 0.1 0 0 0.2 0.4 0.6 0.8 1 1 - Specificity (false positives) ROC Analysis: Age >75 years

  11. ICON Predictor OR 95% CI P NT-proBNP elevado* 24.2 12.6-39.3 <0.00001 Edema intersticial en RX 6.7 3.5-12.8 <0.0001 Ausencia de tos 3.7 1.85-7.7 0.0002 Ortopnea 3.5 2.2-5.5 <0.00001 Crepitantes pulmonares 3.0 2.0-4.5 <0.00001 Uso de diuréticos de asa 2.8 1.8-4.4 <0.0001 Antecedentes de ICC 2.8 1.7-4.6 <0.0001 Ausencia de fiebre 2.6 1.7-4.0 <0.0001 Edad 1.6 1.3-1.8 <0.0001 Frecuencia cardiaca 1.01 1.00-1.02 0.004 Análisis de regresión logística MV 22% 36% *NT-proBNP elevado definido como >450 para pacientes <50 años, >900 pg/ml para pacientes 50-75 años, y >1800 pg/ml para pacientes >75 años

  12. Rule Out Cutoff Points International NT-proBNP Collaboration 300 pg/ml, age independent 99% sensitive 60% specific 98% NPV Punto de corte recomendado en las nuevas guías de la ESC

  13. Patient attending the ED with breathlessness History taking, physical exam, ECG, chest X-ray and NTproBNP NTproBNP >450g/mL - patients <50 a >900pg/mL - patients 50-75 a >1800pg/mL - patients >75a NTproBNP <300pg/mL NTproBNP between 2 cut-points Acute CHF likely Acute CHF unlikely Acute CHF less likely Additional tests

  14. Understanding NT-proBNP in Obesity

  15. The obesity paradox ¿? • Plasma levels of natriuretic peptides appear inversely associated with BMI in both subjects with and without HF. • Natriuretic peptides are lower in overweight and obese patients compared with lean patients Mehra MR et al. JACC 2004;43:1590 Kistorp C et al. Circulation 2005;112:1756. StPeter JV. Clin Chemistry 2006;52:680 Rivera M et al. Eur J Heart Fail 2005;7:1168.

  16. Mechanisms of low NP in obesity Is it a matter of Increased degradation? 22 pts underwent bariatric surgery Parallel increases of BNP and NT-proBNP after weight loss These data refutes the hypothesis that negative correlation between BNP and BMI is due to upregulation of NPR-C because NPR-C do not clear NT-proBNP

  17. Mechanisms of low NP in obesity • Increased degradation • BNP is cleared by NPR-C, abundantly expressed in human adipocytes. • NT-proBNP is not cleared by NPR-C • Reduced synthesis • altered neurohormonal interactions ¿? • Sex steroid hormones ¿? • Substance produced in the lean mass that suppresses either synthesis or release of NP from cardiomyocytes ¿? Das SR et al. Circulation 2005;112:2163 van Kimmenade R et al. JACC 2006;47:886

  18. Obesity, NT-proBNP and Diagnosis

  19. How obesity affects NT-proBNP in the diagnosis of acute HF?ICON BMI- substudy

  20. BMI, NT-proBNP and diagnosis

  21. ROC curves for NT-proBNP / BMI

  22. Utility of recommended NT-proBNP rule-in and rule-out HF cut-points as a function of BMI

  23. NP and obesity for diagnosing acute HF • Age-adjusted rule-in and age-independent rule-out cut-points for NT-proBNP are equally useful for obese and lean patients Bayes-Genis et al. Arch Intern Med 2006: In press • BMI influences the selection of cut-points for BNP in diagnosing acute HF: • 170 ng/L - lean • 54 ng/L - obese Daniels LB et al. Am Heart J 2006;151:999

  24. Obesity, NT-proBNP and Prognosis

  25. How obesity affects the prognostic value of NT-proBNPICON BMI - substudy

  26. BMI, NT-proBNP and prognosis

  27. Hazard ratios across BMI adjusted for NT-proBNP > 986 ng/L Optimal long-term (1 year) NT-proBNP cut-point: 986ng/L Januzzi JL et al. Arch Intern Med 2006;166:315

  28. K-M survival curves across BMI categories Bayes-Genis et al. Arch Intern Med 2006: In press

  29. What about BNP?

  30. BMI, BNP and prognosis Horwich TB et al. JACC 2006;47:85

  31. Diferent prognostic cut-points across BMI Horwich TB et al. JACC 2006;47:85

  32. NP and obesity for long-term risk stratification • One single prognostic cut-point for NT-proBNP (986ng/L) is useful across all BMI categories. Januzzi JL et al. Arch Intern Med 2006;166:315 Bayes-Genis A et al. Arch Intern Med 2006;In press • Optimal BNP cut-points for prediction of death or urgent transplantation are different in the three BMI strata: • 590 ng/L - lean • 491 ng/L - overweight • 343 ng/L - obese Horwich TB et al. JACC 2006;47:85

  33. The obesity paradoxREVISITED In univariable analysis, higher BMI was an independent predictor of survival, with a 4% reduction in the risk of death with every increase of 1 BMI unit (95% CI=0.94-0.99, p=0.002). However, greater BMI was not significantly associated with 1-year mortality once age was added to the model. Thus, the apparent obesity paradox in HF represents an association that is unlikely to be causal

  34. Riñón y NT-proBNP

  35. Subestudio Renal de ICON • 720 pacientes con IC aguda • FGR calculado mediante ecuación MDRD • Supervivencia a 60 días • 84 pacientes fallecieron • 606 pacientes vivos Levey et al. Ann Intern Med 1999;130:461-470

  36. Supervivencia a 60 días

  37. Supervivencia a 60 días

  38. Supervivencia a 60 días

  39. Subestudio Renal de ICON • Los pacientes fueron dicotomizados • Según los niveles de NT-proBNP • Concentración mediana = 4647 pg/mL (=548 pmol/L) • Según FGR • > / < 60 ml/min/1.73m² • 51.8% had GFR < 60 ml/min/1.73m²

  40. Predictores independientes de mortalidad en el análisis multivariado

  41. Predictores independientes de mortalidad en el análisis multivariado

  42. Curvas de K-M según FGR y NT-proBNP Van Kimmenade R et al. JACC 2006 In Press

  43. NT-proBNP monitoring

  44. P=0.004 - 15% - 75% - 50% ER 7 d ER 7 d ER 7 d Death of non CV origin Death of CV origin Survivors Percent NTproBNP reduction during admission and prognosis

  45. 1,0 - 30% 0,8 Sens: 70% Spec: 84% PPV: 47% NPV 94% Accuracy 82% Sensitivity 0,5 AUC 0.79 (0.69-0.94) p=0.001 0,3 0,0 0,8 0,0 0,3 0,5 1,0 1 - Specificity ROC for NTproBNP reduction during hospitalization

  46. N=182 Decrease 30% - 25% Decrease <30% - ~50% Increase 30% - 80% 6 months Prognosis of NTproBNP reduction during hospitalization for CHF Bettencourt P et al. Circulation 2004;110:2168

  47. A Uneventful Follow-up LVEDD: 69 mm LVEF: 16% Baseline W1 M3 W2 W3 W4 Patient with no events during follow-up

  48. death Hospital admission LVEDD: 73 mm LVEF: 20% Baseline M3 W1 W2 W3 W4 Patient with events during follow-up

  49. What’s next? Resynchronization? i.v. inotropes? Adverse prognosis ??????? Worsening HF Good prognosis outpatient follow-up

More Related